Adjuvant ribavirin and longer direct‐acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure-Reference-Cited by-同舟云学术

Adjuvant ribavirin and longer direct‐acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure

Published:2019-07-04 Issue:10 Volume:26 Page:1210-1217
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Lu Mei¹^ORCID,Wu Kuan‐Han¹,Li Jia¹,Moorman Anne C.²,Spradling Philip R.²,Teshale Eyasu H.²,Boscarino Joseph A.³^ORCID,Daida Yihe G.⁴,Schmidt Mark A.⁵,Rupp Loralee B.⁶,Zhang Talan¹,Trudeau Sheri¹^ORCID,Gordon Stuart C.⁷⁸

Affiliation:

1. Department of Public Health Sciences Henry Ford Health System Detroit Michigan

2. Division of Viral Hepatitis National Center for HIV, Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention Atlanta Georgia

3. Department of Epidemiology and Health Services Research Geisinger Clinic Danville Pennsylvania

4. Center for Health Research Kaiser Permanente–Hawai’i Waipahu Hawaii

5. Center for Health Research Kaiser Permanente–Northwest Portland Oregon

6. Center for Health Policy and Health Services Research Henry Ford Health System Detroit Michigan

7. Division of Gastroenterology and Hepatology Henry Ford Health System Detroit Michigan

8. Wayne State University School of Medicine Detroit Michigan

Funder

Centers for Disease Control and Prevention

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13162

Reference16 articles.

1. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks

2. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response

3. Real‐world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment‐naive, genotype 1 hepatitis C‐infected patients

4. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort

5. Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized care approaches to hepatitis C therapy: recent advances and future directions;Expert Review of Anti-infective Therapy;2024-03-11

2. Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis C and Cirrhosis;Advances in Therapy;2024-01-02

3. Broadening and strengthening the health providers caring for patients with chronic hepatitis C may improve continuity of care;Journal of Gastroenterology and Hepatology;2023-12-19

4. A randomized-controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C;Journal of Hepatology;2023-08

5. Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens;Viruses;2023-03-04